These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28685846)

  • 1. Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.
    Verriere B; Gastaud L; Chamorey E; Peyrade F; Deletie E; Bouredji K; Quinsat D; Schiappa R; Thyss A; Re D
    Hematol Oncol; 2018 Feb; 36(1):144-149. PubMed ID: 28685846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
    Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
    Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
    Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
    Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A
    Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
    Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
    Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
    Martínez-Calle N; Hartley S; Ahearne M; Kasenda B; Beech A; Knight H; Balotis C; Kennedy B; Wagner S; Dyer MJS; Smith D; McMillan AK; Miall F; Bishton M; Fox CP
    Br J Haematol; 2019 Mar; 184(6):957-968. PubMed ID: 30548597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
    Wolach O; Bairey O; Lahav M
    Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.
    Tamjid B; Mckendrick J; Schwarer A; Doig R; James P; Hosking P; Hawkes EA
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):226-233. PubMed ID: 28004881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
    Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
    Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
    Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
    Li SC; Chen YC; Evens AM; Lee CC; Liao HF; Yu CC; Tung YT; Su YC
    Am J Hematol; 2010 Oct; 85(10):810-2. PubMed ID: 20730791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.